Magle Chemoswed Holding
4.22 SEK
+2.93 %
Less than 1K followers
MAGLE
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
+2.93 %
-7.46 %
-53.11 %
-76.02 %
-77.19 %
-83.89 %
-87.96 %
-88.23 %
-79.00 %
The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. The Group includes three operational areas. Magle Chemoswed, a contract development and manufacturing organization (CDMO). Magle PharmaCept, an established sales and marketing company for the development and direct sales of the Groups medical technology products, and Magle Biopolymers A/S, a specialized manufacturing organization of Dextran technology.
Read moreMarket cap
127.71M SEK
Turnover
150.1 SEK
Revenue
282.92M
EBIT %
-44.88 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
26/5
2026
General meeting '26
26/5
2026
Extraordinary general meeting '26
31/5
2026
Interim report Q1'26
All
Press releases
3rd party
ShowingAll content types
Kallelse till extra bolagsstämma i Magle Chemoswed Holding AB (publ)
Notice to extraordinary general meeting in Magle Chemoswed Holding AB (publ)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools